{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:52:15Z","timestamp":1771671135267,"version":"3.50.1"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.neuint.2024.105903","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T16:48:21Z","timestamp":1733503701000},"page":"105903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PDE4D inhibitors: Opening a new era of PET diagnostics for Alzheimer's disease"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8660-8339","authenticated-orcid":false,"given":"Luyang","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzong","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangdi","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.neuint.2024.105903_bib1","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s40265-017-0784-3","article-title":"Phosphodiesterase 4 inhibitor therapies for atopic dermatitis: progress and outlook","volume":"77","author":"Ahluwalia","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.neuint.2024.105903_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/1230239","article-title":"Development of white cabbage, coffee, and red onion extracts as natural phosphodiesterase-4B (PDE4B) inhibitors for cognitive dysfunction: in vitro and in silico studies","volume":"2024","author":"Ahmad","year":"2024","journal-title":"Advances in pharmacological and pharmaceutical sciences"},{"key":"10.1016\/j.neuint.2024.105903_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110366","article-title":"Roflumilast ameliorates cognitive deficits in a mouse model of amyloidogenesis and tauopathy: involvement of nitric oxide status, A\u03b2 extrusion transporter ABCB1, and reversal by PKA inhibitor H89","volume":"111","author":"Ashour","year":"2021","journal-title":"Progress in neuro-psychopharmacology & biological psychiatry"},{"issue":"10","key":"10.1016\/j.neuint.2024.105903_bib4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.neuint.2024.105903_bib5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/acs.jcim.7b00137","article-title":"Best practices of computer-aided drug discovery: lessons learned from the development of a preclinical candidate for prostate cancer with a new mechanism of action","volume":"57","author":"Ban","year":"2017","journal-title":"J. Chem. Inf. Model."},{"issue":"5","key":"10.1016\/j.neuint.2024.105903_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/jcbfm.2014.43","article-title":"Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage","volume":"34","author":"Baron","year":"2014","journal-title":"J. Cerebr. Blood Flow Metabol. : official journal of the International Society of Cerebral Blood Flow and Metabolism"},{"issue":"8","key":"10.1016\/j.neuint.2024.105903_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/17460441.2016.1201262","article-title":"A renaissance of neural networks in drug discovery","volume":"11","author":"Baskin","year":"2016","journal-title":"Expet Opin. Drug Discov."},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2967\/jnumed.118.209650","article-title":"In vivo characterization and quantification of neurofibrillary tau PET radioligand (18)F-MK-6240 in humans from alzheimer disease dementia to young controls","volume":"60","author":"Betthauser","year":"2019","journal-title":"J. Nucl. Med. : official publication, Society of Nuclear Medicine"},{"issue":"3","key":"10.1016\/j.neuint.2024.105903_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00894-021-04674-8","article-title":"Generative chemistry: drug discovery with deep learning generative models","volume":"27","author":"Bian","year":"2021","journal-title":"J. Mol. Model."},{"issue":"23","key":"10.1016\/j.neuint.2024.105903_bib10","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2174\/138161208785740027","article-title":"The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses","volume":"14","author":"Bisogno","year":"2008","journal-title":"Curr. Pharmaceut. Des."},{"issue":"14","key":"10.1016\/j.neuint.2024.105903_bib11","doi-asserted-by":"crossref","first-page":"12590","DOI":"10.1074\/jbc.M110.203604","article-title":"PDE4D and PDE4B function in distinct subcellular compartments in mouse embryonic fibroblasts","volume":"286","author":"Blackman","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.neuint.2024.105903_bib12","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.1021\/acs.jmedchem.6b00151","article-title":"From companion diagnostics to theranostics: a new avenue for Alzheimer's disease?","volume":"59","author":"Bolognesi","year":"2016","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.neuint.2024.105903_bib13","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/WNR.0b013e3282f16dca","article-title":"Expression of phosphodiesterase 4 is altered in the brains of subjects with autism","volume":"18","author":"Braun","year":"2007","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jcc.540040211","article-title":"CHARMM: a program for macromolecular energy, minimization, and dynamics calculations","volume":"4","author":"Brooks","year":"1983","journal-title":"J. Comput. Chem."},{"issue":"8","key":"10.1016\/j.neuint.2024.105903_bib15","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1111\/j.1476-5381.2011.01524.x","article-title":"GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses","volume":"164","author":"Bruno","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nbt.1598","article-title":"Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety","volume":"28","author":"Burgin","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"7715","key":"10.1016\/j.neuint.2024.105903_bib17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41586-018-0337-2","article-title":"Machine learning for molecular and materials science","volume":"559","author":"Butler","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.neuint.2024.105903_bib18","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1021\/acs.jnatprod.4c00422","article-title":"Discovery of oxidized p-terphenyls as phosphodiesterase 4 inhibitors from marine-derived fungi","volume":"87","author":"Cai","year":"2024","journal-title":"J. Nat. Prod."},{"issue":"5","key":"10.1016\/j.neuint.2024.105903_bib19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2174\/138955709788167628","article-title":"Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease","volume":"9","author":"Campillo","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"issue":"3","key":"10.1016\/j.neuint.2024.105903_bib20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1021\/jm00081a022","article-title":"QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase","volume":"35","author":"Cardozo","year":"1992","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.neuint.2024.105903_bib21","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1021\/jm00081a023","article-title":"Conformational analyses and molecular-shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase","volume":"35","author":"Cardozo","year":"1992","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.neuint.2024.105903_bib22","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1523\/JNEUROSCI.5851-09.2010","article-title":"Type 4 phosphodiesterase plays different integrating roles in different cellular domains in pyramidal cortical neurons","volume":"30","author":"Castro","year":"2010","journal-title":"J. Neurosci. : the official journal of the Society for Neuroscience"},{"issue":"4","key":"10.1016\/j.neuint.2024.105903_bib23","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1021\/ci9004173","article-title":"Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity","volume":"50","author":"Chen","year":"2010","journal-title":"J. Chem. Inf. Model."},{"issue":"6","key":"10.1016\/j.neuint.2024.105903_bib24","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.drudis.2018.01.039","article-title":"The rise of deep learning in drug discovery","volume":"23","author":"Chen","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"12","key":"10.1016\/j.neuint.2024.105903_bib25","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1021\/jm4004285","article-title":"QSAR modeling: where have you been? Where are you going to?","volume":"57","author":"Cherkasov","year":"2014","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.neuint.2024.105903_bib26","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s00259-016-3363-z","article-title":"Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm","volume":"43","author":"Chiotis","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"3","key":"10.1016\/j.neuint.2024.105903_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/emm.2000.19","article-title":"Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock","volume":"32","author":"Cho","year":"2000","journal-title":"Exp. Mol. Med."},{"issue":"16","key":"10.1016\/j.neuint.2024.105903_bib28","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/jcc.20303","article-title":"The GROMOS software for biomolecular simulation: GROMOS05","volume":"26","author":"Christen","year":"2005","journal-title":"J. Comput. Chem."},{"issue":"12","key":"10.1016\/j.neuint.2024.105903_bib29","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.118.209916","article-title":"Characterization of 3 novel tau radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in healthy controls and in alzheimer subjects","volume":"59","author":"Dean","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.neuint.2024.105903_bib30","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-015-0439-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40265-019-01253-3","article-title":"Apremilast: a review in oral ulcers of beh\u00e7et's disease","volume":"80","author":"Deeks","year":"2020","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/cells10020464","article-title":"Compartmentalized signaling in aging and neurodegeneration","volume":"10","author":"Di Benedetto","year":"2021","journal-title":"Cells"},{"issue":"24","key":"10.1016\/j.neuint.2024.105903_bib33","volume":"101","year":"2023","journal-title":"C&EN Global Enterprise"},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1021\/acs.molpharmaceut.5b00626","article-title":"Molecular imaging of pancreatic cancer with antibodies","volume":"13","author":"England","year":"2016","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11011-018-0374-4","article-title":"Roflumilast ameliorates cognitive impairment in APP\/PS1 mice via cAMP\/CREB\/BDNF signaling and anti-neuroinflammatory effects","volume":"34","author":"Feng","year":"2019","journal-title":"Metab. Brain Dis."},{"issue":"7","key":"10.1016\/j.neuint.2024.105903_bib36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.neuint.2024.105903_bib37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40265-022-01722-2","article-title":"New topical therapies in development for atopic dermatitis","volume":"82","author":"Freitas","year":"2022","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/qsar.19970160202","article-title":"Recent success stories leading to commercializable bioactive compounds with the aid of traditional QSAR procedures","volume":"16","author":"Fujita","year":"1997","journal-title":"Quant. Struct.-Act. Relat."},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/syn.20347","article-title":"In vivo and in vitro measurement of brain phosphodiesterase 4 in rats after antidepressant administration","volume":"61","author":"Fujita","year":"2007","journal-title":"Synapse"},{"key":"10.1016\/j.neuint.2024.105903_bib40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.biopsych.2012.04.030","article-title":"Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-Rolipram positron emission tomography in major depressive disorder","volume":"72","author":"Fujita","year":"2012","journal-title":"Biol. Psychiatr."},{"issue":"22","key":"10.1016\/j.neuint.2024.105903_bib41","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1016\/j.bmcl.2010.09.087","article-title":"Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment","volume":"20","author":"Gallant","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"11","key":"10.1016\/j.neuint.2024.105903_bib42","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1021\/cn3000907","article-title":"Phosphodiesterases as therapeutic targets for Alzheimer's disease","volume":"3","author":"Garc\u00eda-Osta","year":"2012","journal-title":"ACS Chem. Neurosci."},{"issue":"14","key":"10.1016\/j.neuint.2024.105903_bib43","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s40265-015-0463-1","article-title":"Roflumilast: a review in COPD","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/minf.201501008","article-title":"Deep learning in drug discovery","volume":"35","author":"Gawehn","year":"2016","journal-title":"Molecular informatics"},{"issue":"4","key":"10.1016\/j.neuint.2024.105903_bib45","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.neuron.2010.01.014","article-title":"PKA dynamics in a Drosophila learning center: coincidence detection by rutabaga adenylyl cyclase and spatial regulation by dunce phosphodiesterase","volume":"65","author":"Gervasi","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuint.2024.105903_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/323149","article-title":"3D-QSAR and docking studies of a series of \u03b2-carboline derivatives as antitumor agents of PLK1","volume":"2014","author":"Ghasemi","year":"2014","journal-title":"J. Chem."},{"issue":"13","key":"10.1016\/j.neuint.2024.105903_bib47","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","article-title":"Microtubule-associated protein tau. A component of Alzheimer paired helical filaments","volume":"261","author":"Grundke-Iqbal","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.neuint.2024.105903_bib48","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1021\/acs.jmedchem.3c02424","article-title":"Identification of dihydrobenzofuran neolignans as novel PDE4 inhibitors and evaluation of antiatopic dermatitis efficacy in DNCB-induced mice model","volume":"67","author":"Gu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.neuint.2024.105903_bib49","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1021\/acs.jmedchem.9b00193","article-title":"Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of fragile X syndrome and other brain disorders","volume":"62","author":"Gurney","year":"2019","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.neuint.2024.105903_bib50","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1212\/WNL.0b013e31826043a9","article-title":"Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy","volume":"79","author":"Gurol","year":"2012","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.neuint.2024.105903_bib51","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1021\/acschemneuro.3c00222","article-title":"Evaluation of [(18)F]RoSMA-18-d(6) as a CB2 PET radioligand in nonhuman primates","volume":"14","author":"Haider","year":"2023","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1164\/rccm.202009-3533SO","article-title":"The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease","volume":"203","author":"Halpin","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib53","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2967\/jnumed.115.164848","article-title":"18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in alzheimer disease","volume":"57","author":"Harada","year":"2016","journal-title":"J. Nucl. Med. : official publication, Society of Nuclear Medicine"},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuron.2006.09.016","article-title":"A hundred years of Alzheimer's disease research","volume":"52","author":"Hardy","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.neuint.2024.105903_bib55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nbd.2013.08.017","article-title":"Translational PET imaging research","volume":"61","author":"Hargreaves","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"7","key":"10.1016\/j.neuint.2024.105903_bib56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/776","article-title":"Computational protein engineering","volume":"5","author":"Hellinga","year":"1998","journal-title":"Nat. Struct. Biol."},{"issue":"10","key":"10.1016\/j.neuint.2024.105903_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23102520","article-title":"Artificial intelligence in drug design","volume":"23","author":"Hessler","year":"2018","journal-title":"Molecules"},{"issue":"9634","key":"10.1016\/j.neuint.2024.105903_bib58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet (London, England)"},{"issue":"Pt 1","key":"10.1016\/j.neuint.2024.105903_bib59","first-page":"1","article-title":"PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization","volume":"370","author":"Houslay","year":"2003","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1093-3263(03)00153-0","article-title":"Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction","volume":"22","author":"Hu","year":"2003","journal-title":"J. Mol. Graph. Model."},{"issue":"23","key":"10.1016\/j.neuint.2024.105903_bib61","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1016\/j.bmc.2011.09.061","article-title":"Searching for the Multi-Target-Directed Ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H\u2083R and BACE 1 inhibitory activities","volume":"19","author":"Huang","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.neuint.2024.105903_bib62","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/ddr.21222","article-title":"Computational approaches for drug discovery","volume":"75","author":"Hung","year":"2014","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.neuint.2024.105903_bib63","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.12688\/f1000research.11603.1","article-title":"The emerging role of PET imaging in dementia","volume":"6","author":"Iaccarino","year":"2017","journal-title":"F1000Research"},{"issue":"5","key":"10.1016\/j.neuint.2024.105903_bib64","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0896-6273(00)80120-8","article-title":"Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus","volume":"16","author":"Impey","year":"1996","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.neuint.2024.105903_bib65","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1021\/acs.jmedchem.5b02008","article-title":"Docking screens for novel ligands conferring new biology","volume":"59","author":"Irwin","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuint.2024.105903_bib66","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-publhealth-040218-043758","article-title":"Causes and patterns of dementia: an update in the era of redefining Alzheimer's disease","volume":"40","author":"James","year":"2019","journal-title":"Annu. Rev. Publ. Health"},{"issue":"8","key":"10.1016\/j.neuint.2024.105903_bib67","doi-asserted-by":"crossref","DOI":"10.1063\/1.2221680","article-title":"Parallelized-over-parts computation of absolute binding free energy with docking and molecular dynamics","volume":"125","author":"Jayachandran","year":"2006","journal-title":"J. Chem. Phys."},{"issue":"13","key":"10.1016\/j.neuint.2024.105903_bib68","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.bmcl.2019.04.036","article-title":"Facile synthesis of carbon-11-labeled sEH\/PDE4 dual inhibitors as new potential PET agents for imaging of sEH\/PDE4 enzymes in neuroinflammation","volume":"29","author":"Jia","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib69","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/acs.jmedchem.2c01745","article-title":"An empirical quantitative structure-activity relationship equation assists the discovery of high-affinity phosphodiesterase 4D inhibitors as leads to PET radioligands","volume":"66","author":"Jiang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.neuint.2024.105903_bib70","doi-asserted-by":"crossref","first-page":"13768","DOI":"10.1021\/acs.joc.4c01505","article-title":"Difluoromethoxide is a strong leaving group in the photoredox deoxyradiofluorination of 2-phenylpyridines","volume":"89","author":"Jiang","year":"2024","journal-title":"J. Org. Chem."},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib71","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib72","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ana.24825","article-title":"AV-1451 tau and \u03b2-amyloid positron emission tomography imaging in dementia with Lewy bodies","volume":"81","author":"Kantarci","year":"2017","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib73","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.nucmedbio.2006.10.002","article-title":"In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues","volume":"34","author":"Kenk","year":"2007","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.neuint.2024.105903_bib74","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/197192b0","article-title":"Paired helical filaments in electron microscopy of Alzheimer's disease","volume":"197","author":"Kidd","year":"1963","journal-title":"Nature"},{"issue":"167","key":"10.1016\/j.neuint.2024.105903_bib75","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0206-2022","article-title":"Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis","volume":"32","author":"Kolb","year":"2023","journal-title":"Eur. Respir. Rev. : an official journal of the European Respiratory Society"},{"issue":"10","key":"10.1016\/j.neuint.2024.105903_bib76","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","article-title":"Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies","volume":"46","author":"Kroth","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.neuint.2024.105903_bib77","first-page":"1","article-title":"3D-QSAR CoMFA and CoMSIA studies for design of potent human steroid 5 alpha-reductase inhibitors","volume":"22","author":"Kumar","year":"2012","journal-title":"Med. Chem. Res."},{"issue":"3","key":"10.1016\/j.neuint.2024.105903_bib78","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/jm901039z","article-title":"18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective","volume":"53","author":"Kung","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuint.2024.105903_bib79","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/B978-0-444-53485-9.00011-8","article-title":"Positron emission tomography","volume":"135","author":"Lameka","year":"2016","journal-title":"Handb. Clin. Neurol."},{"issue":"8","key":"10.1016\/j.neuint.2024.105903_bib80","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies-still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuint.2024.105903_bib81","first-page":"305","article-title":"Deep learning based imaging data completion for improved brain disease diagnosis","volume":"17","author":"Li","year":"2014","journal-title":"Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention"},{"issue":"17","key":"10.1016\/j.neuint.2024.105903_bib82","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1523\/JNEUROSCI.5851-09.2010","article-title":"Type 4 phosphodiesterase plays different integrating roles in different cellular domains in pyramidal cortical neurons","volume":"30","author":"Liliana","year":"2010","journal-title":"J. Neurosci."},{"issue":"14","key":"10.1016\/j.neuint.2024.105903_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25143250","article-title":"Relevant applications of generative adversarial networks in drug design and discovery: molecular de novo design, dimensionality reduction, and de novo peptide and protein design","volume":"25","author":"Lin","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.neuint.2024.105903_bib84","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41392-019-0063-8","article-title":"History and progress of hypotheses and clinical trials for Alzheimer's disease","volume":"4","author":"Liu","year":"2019","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"25","key":"10.1016\/j.neuint.2024.105903_bib85","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.7150\/jca.35443","article-title":"High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma","volume":"10","author":"Liu","year":"2019","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib86","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib87","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1098-2396(199901)31:1<41::AID-SYN6>3.0.CO;2-S","article-title":"Imaging of cAMP-specific phosphodiesterase-IV: comparison of [11C]rolipram and [11C]Ro 20-1724 in rats","volume":"31","author":"Lourenco","year":"1999","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/j.neuint.2024.105903_bib88","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0969-8051(01)00206-2","article-title":"Characterization of r-[11C]rolipram for PET imaging of phosphodieterase-4: in vivo binding, metabolism, and dosimetry studies in rats","volume":"28","author":"Lourenco","year":"2001","journal-title":"Nucl. Med. Biol."},{"issue":"4","key":"10.1016\/j.neuint.2024.105903_bib89","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.lfs.2006.01.010","article-title":"Increasing synaptic noradrenaline, serotonin and histamine enhances in vivo binding of phosphodiesterase-4 inhibitor (R)-[11C]rolipram in rat brain, lung and heart","volume":"79","author":"Lourenco","year":"2006","journal-title":"Life Sci."},{"issue":"23","key":"10.1016\/j.neuint.2024.105903_bib90","doi-asserted-by":"crossref","first-page":"10250","DOI":"10.1523\/JNEUROSCI.19-23-10250.1999","article-title":"Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus","volume":"19","author":"Lu","year":"1999","journal-title":"J. Neurosci. : the official journal of the Society for Neuroscience"},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib91","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.nbd.2008.12.008","article-title":"Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics","volume":"34","author":"Maetzler","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"10","key":"10.1016\/j.neuint.2024.105903_bib92","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1021\/jm040217u","article-title":"The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases","volume":"48","author":"Manallack","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuint.2024.105903_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2022.102417","article-title":"Computer-aided drug design, quantum-mechanical methods for biological problems","volume":"75","author":"Manathunga","year":"2022","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib94","first-page":"407","article-title":"Cyclic nucleotide phosphodiesterases (PDEs): diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents","volume":"82","author":"Manganiello","year":"1999","journal-title":"Thromb. Haemostasis"},{"issue":"6","key":"10.1016\/j.neuint.2024.105903_bib95","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.neuint.2024.105903_bib96","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.semnuclmed.2012.07.001","article-title":"Development of positron emission tomography \u03b2-amyloid plaque imaging agents","volume":"42","author":"Mathis","year":"2012","journal-title":"Semin. Nucl. Med."},{"issue":"9","key":"10.1016\/j.neuint.2024.105903_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024392","article-title":"Cyclic AMP control measured in two compartments in HEK293 cells: phosphodiesterase K(M) is more important than phosphodiesterase localization","volume":"6","author":"Matthiesen","year":"2011","journal-title":"PLoS One"},{"issue":"5612","key":"10.1016\/j.neuint.2024.105903_bib98","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/267585a0","article-title":"Dynamics of folded proteins","volume":"267","author":"McCammon","year":"1977","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.neuint.2024.105903_bib99","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","article-title":"Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015","volume":"26","author":"Mehta","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib100","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2011","journal-title":"Curr. Comput. Aided Drug Des."},{"issue":"3","key":"10.1016\/j.neuint.2024.105903_bib101","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12603-019-1162-5","article-title":"What is the physiological function of amyloid-beta protein?","volume":"23","author":"Morley","year":"2019","journal-title":"J. Nutr. Health Aging"},{"issue":"14","key":"10.1016\/j.neuint.2024.105903_bib102","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"issue":"8","key":"10.1016\/j.neuint.2024.105903_bib103","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0165-6147(96)10035-3","article-title":"Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition","volume":"17","author":"M\u00fcller","year":"1996","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.neuint.2024.105903_bib104","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1039\/D0CS00098A","article-title":"QSAR without borders","volume":"49","author":"Muratov","year":"2020","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nm.4011","article-title":"Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling","volume":"22","author":"Myeku","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuint.2024.105903_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110822","article-title":"Phosphodiesterase Inhibitors Say NO to Alzheimer\u2019s Disease","author":"Nabavi","year":"2019","journal-title":"Food Chem. Toxicol. 134, 110822"},{"issue":"12","key":"10.1016\/j.neuint.2024.105903_bib107","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1016\/j.bmcl.2009.04.121","article-title":"Discovery of selective PDE4B inhibitors","volume":"19","author":"Naganuma","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuint.2024.105903_bib108","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3389\/fphar.2018.01275","article-title":"QSAR-based virtual screening: advances and applications in drug discovery","volume":"9","author":"Neves","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuint.2024.105903_bib109","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and Alzheimer's disease","volume":"34","author":"O'Brien","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"issue":"7","key":"10.1016\/j.neuint.2024.105903_bib110","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopsych.2012.07.017","article-title":"Evidence for global reduction in brain cyclic adenosine monophosphate signaling in depression","volume":"72","author":"O'Donnell","year":"2012","journal-title":"Biol. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuint.2024.105903_bib111","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tips.2004.01.003","article-title":"Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4)","volume":"25","author":"O'Donnell","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuint.2024.105903_bib112","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neurobiolaging.2020.10.004","article-title":"Increased isoform-specific phosphodiesterase 4D expression is associated with pathology and cognitive impairment in Alzheimer's disease","volume":"97","author":"Paes","year":"2021","journal-title":"Neurobiol. Aging"},{"issue":"11","key":"10.1016\/j.neuint.2024.105903_bib113","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/13543770903313753","article-title":"PDE4 inhibitors: a review of current developments (2005 - 2009)","volume":"19","author":"Pag\u00e8s","year":"2009","journal-title":"Expert Opin. Ther. Pat."},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib114","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"19","key":"10.1016\/j.neuint.2024.105903_bib115","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.1021\/acs.jmedchem.9b02170","article-title":"Advances in the development of phosphodiesterase-4 inhibitors","volume":"63","author":"Peng","year":"2020","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.neuint.2024.105903_bib116","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1038\/npp.2014.154","article-title":"The PDE4 inhibitor HT-0712 improves hippocampus-dependent memory in aged mice","volume":"39","author":"Peters","year":"2014","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"issue":"18","key":"10.1016\/j.neuint.2024.105903_bib117","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.2174\/0929867323666160418114826","article-title":"Considerations in the development of reversibly binding PET radioligands for brain imaging","volume":"23","author":"Pike","year":"2016","journal-title":"Curr. Med. Chem."},{"issue":"7","key":"10.1016\/j.neuint.2024.105903_bib118","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-014-0218-4","article-title":"Apremilast: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.neuint.2024.105903_bib119","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0079-6468(08)00202-6","article-title":"PDE4 inhibitors - a review of the current field","volume":"47","author":"Press","year":"2009","journal-title":"Prog. Med. Chem."},{"issue":"9","key":"10.1016\/j.neuint.2024.105903_bib120","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","article-title":"Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease","volume":"26","author":"Prickaerts","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"23","key":"10.1016\/j.neuint.2024.105903_bib121","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1212\/WNL.0b013e31823b9c5e","article-title":"Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD","volume":"77","author":"Rabinovici","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neuint.2024.105903_bib122","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1158\/1078-0432.CCR-0688-3","article-title":"Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging","volume":"10","author":"Rajendran","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.neuint.2024.105903_bib123","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1021\/acschemneuro.0c00244","article-title":"Therapeutic potential of phosphodiesterase inhibitors against neurodegeneration: the perspective of the medicinal chemist","volume":"11","author":"Ribaudo","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"7","key":"10.1016\/j.neuint.2024.105903_bib124","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI0215506","article-title":"Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis","volume":"110","author":"Robichaud","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.neuint.2024.105903_bib125","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00259-019-04399-0","article-title":"[18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease","volume":"46","author":"Sanabria Boh\u00f3rquez","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.neuint.2024.105903_bib126","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3389\/fimmu.2019.01727","article-title":"Targeting phosphodiesterases-towards a tailor-made approach in multiple sclerosis treatment","volume":"10","author":"Schepers","year":"2019","journal-title":"Front. Immunol."},{"issue":"204","key":"10.1016\/j.neuint.2024.105903_bib127","first-page":"1","article-title":"Phosphodiesterase inhibitors: history of pharmacology","author":"Schudt","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"issue":"Pt 5","key":"10.1016\/j.neuint.2024.105903_bib128","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/brain\/aww023","article-title":"Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages","volume":"139","author":"Schwarz","year":"2016","journal-title":"Brain : J. Neurol."},{"issue":"12","key":"10.1016\/j.neuint.2024.105903_bib129","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.apradiso.2007.04.020","article-title":"Determination of residual Kryptofix 2.2.2 levels in [18F]-labeled radiopharmaceuticals for human use","volume":"65","author":"Scott","year":"2007","journal-title":"Appl. Radiat. Isot."},{"issue":"7698","key":"10.1016\/j.neuint.2024.105903_bib130","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nature25978","article-title":"Planning chemical syntheses with deep neural networks and symbolic AI","volume":"555","author":"Segler","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neuint.2024.105903_bib131","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1875036201307010063","article-title":"QSAR and its role in target-ligand interaction","volume":"7","author":"Singh","year":"2015","journal-title":"Open Bioinf. J."},{"key":"10.1016\/j.neuint.2024.105903_bib132","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuropharm.2012.11.009","article-title":"Etazolate, an \u03b1-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice","volume":"67","author":"Siopi","year":"2013","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuint.2024.105903_bib133","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/jamaneurol.2018.3692","article-title":"Correlation of in vivo [18F]flortaucipir with postmortem alzheimer disease tau pathology","volume":"76","author":"Smith","year":"2019","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.neuint.2024.105903_bib134","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2174\/156720511795745375","article-title":"In vivo human amyloid imaging","volume":"8","author":"Sojkova","year":"2011","journal-title":"Curr. Alzheimer Res."},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib135","first-page":"129","article-title":"Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease","volume":"11","author":"Soto","year":"2005","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"3","key":"10.1016\/j.neuint.2024.105903_bib136","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjp.2008.307","article-title":"PDE4 inhibitors: current status","volume":"155","author":"Spina","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuint.2024.105903_bib137","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/biof.1385","article-title":"Neuroprotective effects of honokiol: from chemistry to medicine","volume":"43","author":"Talarek","year":"2017","journal-title":"Biofactors"},{"key":"10.1016\/j.neuint.2024.105903_bib138","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fnagi.2018.00067","article-title":"Gray matter network disruptions and regional amyloid beta in cognitively normal adults","volume":"10","author":"Ten Kate","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuint.2024.105903_bib139","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00005072-196310000-00005","article-title":"The fine structure of neurofibrillary tangles in ALZHEIMER'S disease","volume":"22","author":"Terry","year":"1963","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"8","key":"10.1016\/j.neuint.2024.105903_bib140","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202000028","article-title":"Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds","volume":"39","author":"Ton","year":"2020","journal-title":"Molecular informatics"},{"issue":"9","key":"10.1016\/j.neuint.2024.105903_bib141","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000036","article-title":"Exploration of dual fatty acid amide hydrolase and cholinesterase inhibitory potential of some 3-hydroxy-3-phenacyloxindole analogs","volume":"353","author":"Tripathi","year":"2020","journal-title":"Arch. Pharmazie"},{"issue":"6\u20137","key":"10.1016\/j.neuint.2024.105903_bib142","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/minf.201000061","article-title":"Best practices for QSAR model development, validation, and exploitation","volume":"29","author":"Tropsha","year":"2010","journal-title":"Molecular informatics"},{"issue":"8","key":"10.1016\/j.neuint.2024.105903_bib143","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/01.WCB.0000126974.07553.86","article-title":"Transient focal ischemia affects the cAMP second messenger system and coupled dopamine D1 and 5-HT1A receptors in the living monkey brain: a positron emission tomography study using microdialysis","volume":"24","author":"Tsukada","year":"2004","journal-title":"J. Cerebr. Blood Flow Metabol. : official journal of the International Society of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.neuint.2024.105903_bib144","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4236\/cmb.2019.93007","article-title":"Molecular docking and pharmacological property analysis of phytochemicals from clitoria ternatea as potent inhibitors of cell cycle checkpoint proteins in the cyclin\/CDK pathway in cancer cells","volume":"9","author":"Ullah","year":"2019","journal-title":"Comput. Mol. Biosci."},{"issue":"6","key":"10.1016\/j.neuint.2024.105903_bib145","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","article-title":"Applications of machine learning in drug discovery and development","volume":"18","author":"Vamathevan","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.neuint.2024.105903_bib146","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1021\/acsmedchemlett.0c00088","article-title":"The advent of generative chemistry","volume":"11","author":"Vanhaelen","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuint.2024.105903_bib147","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1146\/annurev-biochem-061516-045049","article-title":"Propagation of protein aggregation in neurodegenerative diseases","volume":"88","author":"Vaquer-Alicea","year":"2019","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.neuint.2024.105903_bib148","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","article-title":"Imaging tau and amyloid-\u03b2 proteinopathies in Alzheimer disease and other conditions","volume":"14","author":"Villemagne","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"20","key":"10.1016\/j.neuint.2024.105903_bib149","doi-asserted-by":"crossref","first-page":"13217","DOI":"10.1073\/pnas.172504199","article-title":"Amyloid beta -peptide inhibition of the PKA\/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling","volume":"99","author":"Vitolo","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"9","key":"10.1016\/j.neuint.2024.105903_bib150","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1021\/acschemneuro.0c00077","article-title":"Evaluation of subtype-selective inhibitors for positron emission tomography imaging of brain phosphodiesterase-4D","volume":"11","author":"Wakabayashi","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"9","key":"10.1016\/j.neuint.2024.105903_bib151","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.neuint.2024.105903_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116361","article-title":"Discovery of a triphenylamine-based ligand that targets mitochondrial DNA G-quadruplexes and activates the cGAS-STING immunomodulatory pathway","volume":"269","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.neuint.2024.105903_bib153","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0022-2836(76)90311-9","article-title":"Theoretical studies of enzymic reactions: dielectric, electrostatic and steric stabilization of the carbonium ion in the reaction of lysozyme","volume":"103","author":"Warshel","year":"1976","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.neuint.2024.105903_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106278","article-title":"Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement","volume":"130","author":"Wei","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"24","key":"10.1016\/j.neuint.2024.105903_bib155","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1073\/pnas.82.24.8729","article-title":"Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related","volume":"82","author":"Wong","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"13","key":"10.1016\/j.neuint.2024.105903_bib156","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1021\/acs.jmedchem.7b01370","article-title":"Novel phosphodiesterase inhibitors for cognitive improvement in alzheimer's disease","volume":"61","author":"Wu","year":"2018","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.neuint.2024.105903_bib157","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1021\/acs.molpharmaceut.3c00717","article-title":"Synthesis and bioevaluation of 2-styrylquinoxaline derivatives as tau-PET tracers","volume":"20","author":"Wu","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.neuint.2024.105903_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116576","article-title":"Discovery of 7-alkoxybenzofurans as PDE4 inhibitors with hepatoprotective activity in D-GalN\/LPS-induced hepatic sepsis","volume":"275","author":"Xia","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuint.2024.105903_bib159","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.662451","article-title":"Roflumilast suppresses adipogenic differentiation via AMPK mediated pathway","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"11","key":"10.1016\/j.neuint.2024.105903_bib160","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1021\/jm400312y","article-title":"Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand","volume":"56","author":"Zhang","year":"2013","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.neuint.2024.105903_bib161","doi-asserted-by":"crossref","first-page":"8538","DOI":"10.1021\/acs.jmedchem.7b01050","article-title":"The discovery of a novel phosphodiesterase (PDE) 4B-preferring radioligand for positron emission tomography (PET) imaging","volume":"60","author":"Zhang","year":"2017","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.neuint.2024.105903_bib162","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.drudis.2017.08.010","article-title":"From machine learning to deep learning: progress in machine intelligence for rational drug discovery","volume":"22","author":"Zhang","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.neuint.2024.105903_bib163","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/s41386-018-0178-6","article-title":"Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice","volume":"43","author":"Zhang","year":"2018","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/j.neuint.2024.105903_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112629","article-title":"Research progress of (18)F labeled small molecule positron emission tomography (PET) imaging agents","volume":"205","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.neuint.2024.105903_bib165","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1021\/acs.jmedchem.3c02087","article-title":"Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as novel PDE4 inhibitors for the treatment of alcohol use disorder and alcoholic liver diseases","volume":"67","author":"Zheng","year":"2024","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.neuint.2024.105903_bib166","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1039\/C3CS60430F","article-title":"PET\/SPECT imaging agents for neurodegenerative diseases","volume":"43","author":"Zhu","year":"2014","journal-title":"Chem. Soc. Rev."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018624002304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018624002304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:18:55Z","timestamp":1736399935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018624002304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":166,"alternative-id":["S0197018624002304"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2024.105903","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PDE4D inhibitors: Opening a new era of PET diagnostics for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2024.105903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105903"}}